Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy

O'Gara, 2013, ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, e78, 10.1016/j.jacc.2012.11.019 Jneid, 2012, J Am Coll Cardiol, 60, 645, 10.1016/j.jacc.2012.06.004 Levine, 2011, ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, J Am Coll Cardiol, 58, e44, 10.1016/j.jacc.2011.08.007 Nikolsky, 2009, Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, J Am Coll Cardiol, 54, 1293, 10.1016/j.jacc.2009.07.019 Abraham, 2010, Circulation, 122, 2619, 10.1161/CIR.0b013e318202f701 Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 301, 937, 10.1001/jama.2009.261 Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, CMAJ, 180, 713, 10.1503/cmaj.082001 Huang, 2010, Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention, Am J Cardiol, 105, 1705, 10.1016/j.amjcard.2010.01.348 Stockl, 2010, Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor, Arch Intern Med, 170, 704, 10.1001/archinternmed.2010.34 Ray, 2010, Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study, Ann Intern Med, 152, 337, 10.7326/0003-4819-152-6-201003160-00003 Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Hollopeter, 2001, Identification of the platelet ADP receptor targeted by antithrombotic drugs, Nature, 409, 202, 10.1038/35051599 Collet, 2009, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, Lancet, 373, 309, 10.1016/S0140-6736(08)61845-0 Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, 354, 10.1056/NEJMoa0809171 Yamamoto, 2011, Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy, J Cardiol, 57, 194, 10.1016/j.jjcc.2010.10.007 Hokimoto, 2014, Impact of CYP2C19 Polymorphism and Proton Pump Inhibitors on Platelet Reactivity to Clopidogrel and Clinical Outcomes Following Stent Implantation, Thromb Res, 133, 599, 10.1016/j.thromres.2014.01.003 Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227 Li, 2004, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities, Drug Metab Dispos, 32, 821, 10.1124/dmd.32.8.821 Bhatt, 2010, Clopidogrel with or without omeprazole in coronary artery disease, N Engl J Med, 363, 1909, 10.1056/NEJMoa1007964 McKeage, 2008, Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults, Drugs, 68, 1571, 10.2165/00003495-200868110-00009 Richards, 1993, Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs, Hum Mol Genet, 2, 159, 10.1093/hmg/2.2.159 de Morais, 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem, 269, 15419, 10.1016/S0021-9258(17)40694-6 Kubota, 1996, Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population, Clin Pharmacol Ther, 60, 661, 10.1016/S0009-9236(96)90214-3 Thygesen, 2012, Third universal definition of myocardial infarction, Eur Heart J, 33, 2551, 10.1093/eurheartj/ehs184 Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Angiolillo, 2007, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives, J Am Coll Cardiol, 49, 1505, 10.1016/j.jacc.2006.11.044 Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 Hochholzer, 2006, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement, J Am Coll Cardiol, 48, 1742, 10.1016/j.jacc.2006.06.065 Xie, 1999, Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world, Pharmacogenetics, 9, 539, 10.1097/00008571-199910000-00001 Siller-Matula, 2009, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel, Am Heart J, 157, e1 El-Halabi, 2013, CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel, J Cardiovasc Pharmacol, 62, 41, 10.1097/FJC.0b013e31828ecf44 Sibbing, 2009, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel, Thromb Haemost, 101, 714, 10.1160/TH08-12-0808 Man, 2010, Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans, J Clin Pharmacol, 50, 929, 10.1177/0091270009355161 Hulot, 2010, Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis, J Am Coll Cardiol, 56, 134, 10.1016/j.jacc.2009.12.071 Kimura, 2010, Circulation, 122, 52, 10.1161/CIRCULATIONAHA.109.903955 Roe, 2012, Prasugrel versus clopidogrel for acute coronary syndromes without revascularization, N Engl J Med, 367, 1297, 10.1056/NEJMoa1205512 Suh, 2011, J Am Coll Cardiol, 57, 280, 10.1016/j.jacc.2010.08.631 Price, 2011, Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial, JAMA, 305, 1097, 10.1001/jama.2011.290 Frelinger, 2013, J Am Coll Cardiol, 61, 872, 10.1016/j.jacc.2012.11.040 Food